drugset / Trial / NCT05411705
Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury
Phase 4
Unknown
165 enrolled
The First Affiliated Hospital of Dalian Medical University
Anqing Municipal Hospital · collabBeijing Sanhuan Cancer Hospital · collabBethune Charitable Foundation · collabCancer Institute and Hospital, Chinese Academy of Medical Sciences · collabChinese PLA General Hospital · collabHebei Medical University Fourth Hospital · collabHenan Cancer Hospital · collabHenan Provincial People's Hospital · collabLiaoning Cancer Hospital & Institute · collabPeking University Shougang Hospital · collabShanxi Province Cancer Hospital · collabThe Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China · collabTianjin Medical University Cancer Institute and Hospital · collabTongji Hospital · collabUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To assess the efficacy and safety of an optimised dosing regimen of rhTPO's prophylactic treatment of cancer treatment-induced thrombocytopenia(CTIT) and to explore the cardioprotective effect of rhTPO in cancer patients with high risk of treatment-induced cardiac injury.
Timeline
- Start
- 2022-06-06
- Primary completion
- 2024-06
- Completion
- 2024-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | recombinant human thrombopoietin | Protein / enzyme biologic | 300 iu/kg | Subcutaneous |